Henry Waxman Debunks Pharmaceutical Industry Claims of Innovation Loss, Again
In a blog post for Health Affairs, Chairman Henry Waxman debunks the age-old industry claim that lower drug costs mean a loss of drug innovation, noting they made the same unsubstantiated claim back in the 1980s during debate on the Hatch-Waxman Act.
Henry Waxman Discusses The Lower Drug Costs Now Act in Health Affairs
In a piece written for Health Affairs this week, our Chairman Henry Waxman discusses the broken pharmaceutical marketplace, how empowering Medicare to negotiate prices with the pharmaceutical industry will make prescription drugs more affordable for everyone, and why we need the Lower Drug Costs Now Act.
In a piece written for Health Affairs this week, Health Practice Managing Director Kristi Martin joins Jonathan Foley of Westcott Partners and Rob Shriver of IdeaCrew to discuss the Affordable Care Act’s Multi-State Plan Program, lessons learned from its demise and how we can use those lessons to inform discussion on the public option.